表柔比星联合紫杉醇新辅助化疗对乳腺癌保乳术患者血清肿瘤标志物及生命质量的影响

Effect of epirubicin combined with paclitaxel neoadjuvant chemotherapy on serum tumor markers and quality of life in patients with breast conserving surgery for breast cancer

目的探讨表柔比星联合紫杉醇新辅助化疗对乳腺癌保乳术患者血清肿瘤标志物及生命质量的影响。方法选取2019年5月至2021年4月九江市第一人民医院收治的82例乳腺癌患者作为研究对象,根据不同术前化疗用药方案分为观察组与对照组,每组41例。两组均采取保乳术切除病灶,对照组采用表柔比星化疗治疗,观察组在对照组基础上联合紫杉醇新辅助化疗方案治疗,比较两组治疗前后血清肿瘤标志物、生命质量评分及不良反应发生情况。结果治疗后,两组β2-微球蛋白(β2-MG)、癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原15-3(CA15-3)及甲壳质酶蛋白-40(YKL-40)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组生理功能、情感功能、社会功能、总分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论表柔比星联合紫杉醇辅助化疗乳腺癌保乳手术患者,能有效降低血清肿瘤标志物水平,提高生命质量,且不良反应较少,值得临床推广应用。

Objective To investigate the effect of epirubicin combined with paclitaxel neoadjuvant chemotherapy on serum tumor markers and quality of life in patients with breast conserving surgery for breast cance.Methods 82 patients with breast cancer admitted to Jiujiang First People's Hospital from May 2019 to April 2021 were selected as the research subjects,they were divided into the observation group and the control group according to different preoperative chemotherapy regimens,with 41 cases in each group.Both groups were treated with breast conserving surgery to remove the lesions,the control group was treated with epirubicin chemotherapy,and the observation group was treated with paclitaxel neoadjuvant chemotherapy on the basis of the control group,the serum tumor markers,quality of life scores before and after treatment and adverse reactions were compared between the two groups.Results After treatment,the levels ofβ2-microglobulin(β2-MG),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 15-3(CA15-3)and chitinase protein-40(YKL-40)of the two groups were lower than those before treatment,and the observation group was lower than the control group,the differences were statistically significant(P<0.05).After treatment,the physiological function,emotional function,social function and total score of the two groups were higher than those before treatment,and the observation group was higher than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Epirubicin combined with paclitaxel adjuvant chemotherapy for breast cancer patients undergoing breast-conserving surgery can effectively reduce the level of serum tumor markers,improve the quality of life,and have fewer adverse reactions,which is worthy of clinical promotion and application.